EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
7:00am - 8:00am 60 mins
Info
Continental Breakfast - Hilton Union Square

Hilton Union Square, Grand Ballroom

7:00am - 5:00pm 600 mins
Info
Registration and Tabletop Exhibit Open - Hilton Union Square

Hilton Union Square, Plaza A, Lobby Level

8:00am - 8:55am 55 mins
Info
The year of RNA and the start of a new era - Hilton Union Square
  • Moderator Mani Foroohar - Managing Director, Senior Research Analyst, Leerink Partners
  • Panelist Franz-Werner Haas - COO, CureVac
  • Panelist Robert Habib - CEO, MiNA Therapeutics
  • Panelist Vanessa King - CEO, Virion Biotherapeutics
  • Panelist Sean Marett - CBO and CCO, BioNTech
  • Panelist Romesh Subramanian - Entrepreneur-in-Residence, Atlas Venture

Hilton Union Square, Yosemite A

The range of RNA therapeutic modalities has expanded significantly since the first-mover companies such as Alnylam, Ionis and Santaris appeared on the global stage. Today, the industry has propelled a variety of novel approaches into the clinic such as small activating RNAs, microRNAs and has been able to leverage mRNAs to develop uniquely personalized medicine for each individual patient. Many of initial hurdles in delivery or efficacy have also been addressed making it possible to realize the full potential of RNA therapies. What will 2019 bring?

8:00am - 8:55am 55 mins
Info
Rare and orphan diseases: The biotech industry poised to make a dent in treatment and diagnosis - Hilton Union Square
  • Moderator Edward Tenthoff - Senior Research Analyst, Piper Jaffray & Co.
  • Panelist Jim Healy - General Partner, Sofinnova Ventures
  • Panelist Philip Katz - Partner, Hogan Lovells
  • Panelist Denise Scots-Knight - CEO and Founder, Mereo Biopharma Group plc
  • Panelist David P. Snow - CBO, Eloxx Pharmaceuticals

Hilton Union Square, Yosemite C

There are an estimated 7,000+ rare and orphan diseases, and today there are therapies for about 600 rare diseases. With regulatory benefits of the orphan drug act, new technologies including gene and cell therapy and gene editing, market exclusivity and pricing advantages, many biotech companies and big pharma are focusing on orphan diseases. But some counter that premium pricing will break the US healthcare system and are limiting access to care. What is the cost of life extension or even potentially a cure for a debilitating, life-threatening disease?

8:00am - 5:00pm 540 mins
Info
One-to-one meetings - Hilton Union Square

Hilton Union Square, Grand Ballroom

8:30am - 12:00pm 210 mins
Info
Company Presentations - Hilton Union Square

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

12:00pm - 1:45pm 105 mins
Info
Lunch Plenary: The intersection of policy and sentiment: The impact on the industry and the outlook for the future - Hilton Union Square
  • Moderator Wade Ackerman - Partner, Covington & Burling LLP
  • Panelist Rachel King - CEO, GlycoMimetics, Inc.
  • Panelist Jonathan S. Leff - Partner and Chairman, Deerfield Management and Deerfield Institute
  • Panelist Joe Panetta - President and CEO, Biocom
  • Panelist Rick R. Suarez - VP, US Market Access, AstraZeneca

Hilton Union Square, Imperial Ballroom

The biotechnology and healthcare sector is being buffeted by a multitude of forces, including public sentiment around issues like drug pricing. Policymakers are as active as ever, addressing issues like the opioid epidemic, emerging technologies, the rapid integration of digital technologies with medicine, and the overall cost of healthcare. Add to the mix a public and private market whose enthusiasm for this sector has been at an all-time high for a sustained period of time. This panel will discuss the key public policy issues affecting the industry and address the question of how this sector will evolve.

1:45pm - 5:00pm 195 mins
Info
Company Presentations - Hilton Union Square

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

2:00pm - 2:55pm 55 mins
Info
Early seed alternative financing - Hilton Union Square
  • Moderator Ben Johnson - Managing Director, Head, National Early Stage Life Science, SVB Silicon Valley Bank
  • Panelist Grace E. Colón - President and CEO, InCarda Therapeutics Inc
  • Panelist Natalie Dakers - President and CEO, Accel-Rx
  • Panelist Hakan Goker - Senior Investment Director, M-Ventures
  • Panelist Lesley Stolz - Head, JLABS CA, Johnson and Johnson Innovation, JLABS

Hilton Union Square, Franciscan A

4:30pm - 5:15pm 45 mins
Info
The Readout Live: A conversation with STAT's biotech team - Hilton Union Square
  • Panelist Adam Feuerstein - Senior Writer, STAT
  • Panelist Damian Garde - National Biotech Reporter, STAT
  • Panelist Matthew Herper - Senior Writer, Medicine, STAT
  • Panelist Rebecca Robbins - San Francisco Correspondent, STAT

 Hilton Union Square, Imperial Ballroom

After days of trekking in and around Union Square, join STAT's biotech team for a no-holds-barred conversation about the week that was and the year to come. Reporters Adam Feuerstein, Damian Garde, and Rebecca Robbins will break down the most important news stories that you should take away from the week. Then they'll talk about the biggest biotech stories and newsmakers to watch in 2019. Come ready to ask them questions.

5:15pm - 6:15pm 60 mins
Info
Closing reception - Hilton Union Square

Hilton Union Square, Grand Ballroom

Showing of Streams
5:15pm - 6:15pm

Closing reception - Hilton Union Square

Hilton Union Square, Grand Ballroom

More